đź“ąHerman Goossens, Emeritus Professor at the University of Antwerp, explains why sustained investment in R&D, clinical trials, manufacturing and equitable access is essential to secure the future of antibiotics.
@gardp.bsky.social
@gardp.bsky.socialđź“ąHerman Goossens, Emeritus Professor at the University of Antwerp, explains why sustained investment in R&D, clinical trials, manufacturing and equitable access is essential to secure the future of antibiotics.
@gardp.bsky.socialOn #WorldSepsisDay, we’re reminded that treating sepsis depends on having antibiotics that work. As resistance grows, those options are shrinking.
“Invest in Sepsis – Save Lives” means investing in the treatments we need to stay ahead.
@gardp.bsky.socialIn Germany, earlier diagnosis helps patients receive treatment for sepsis sooner, but AMR is making infections harder to treat.
Peter Beyer writes in Tagesspiegel Background on why sepsis investment must include new antibiotics: tinyurl.com/3pt7tama